Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune-related adverse events during treatment with immune checkpoint inhibitors

dc.contributor.author	Baumgarten, Louisa von
dc.date.accessioned	2026-10-13T06:53:29Z
dc.date.available	2026-10-13T06:53:29Z
dc.date.issued	2025
dc.identifier.issn	0020-7136
dc.identifier.uri	http://hdl.handle.net/10900/184260
dc.language.iso	en	de_DE
dc.publisher	Hoboken : Wiley	de_DE
dc.relation.uri	http://dx.doi.org/10.1002/ijc.35328	de_DE
dc.subject.ddc	610	de_DE
dc.title	Increased serum NfL and GFAP levels indicate different subtypes of neurologic immune-related adverse events during treatment with immune checkpoint inhibitors	de_DE
dc.type	Article	de_DE
utue.quellen.id	20250630000000_02060
utue.publikation.seiten	1961-1971	de_DE
utue.personen.roh	Schmitt, Christina
utue.personen.roh	Mueller, Katharina J.
utue.personen.roh	Tiedt, Steffen
utue.personen.roh	Kramer, Nora
utue.personen.roh	Manger, Isabel
utue.personen.roh	Knauss, Samuel
utue.personen.roh	Mueller-Jensen, Leonie
utue.personen.roh	Huehnchen, Petra
utue.personen.roh	Boehmerle, Wolfgang
utue.personen.roh	Schoeberl, Florian
utue.personen.roh	Heinzerling, Lucie
utue.personen.roh	von Baumgarten, Louisa
dcterms.isPartOf.ZSTitelID	International Journal of Cancer	de_DE
dcterms.isPartOf.ZS-Issue	10	de_DE
dcterms.isPartOf.ZS-Volume	156	de_DE